Classifications: beta-lactam antibiotic; carbapenem antibiotic; Therapeutic: antibiotic
Pregnancy Category: B
500 mg single-use vials
Inhibits essential penicillin-binding proteins resulting in inhibition of bacterial cell wall synthesis, resulting in bacterial
Bacteriocidal against aerobic and anaerobic gram-negative and -positive bacteria, and effectively resolves infection.
Single agent treatment of complicated intra-abdominal infections and urinary tract infections, including pyelonephritis
caused by susceptible Escherichia, Klebsiella, Pseudomonas, Bacteroides, Streptococcus, Peptostreptococcus, Proteus, and Acinetobacter organisms.
Hypersensitivity to doripenem, or beta-lactam antibiotics; multiple allergies; inhalation route.
Hypersensitivity to cephalosporins, penicillins; moderate to severe renal impairment; older adults; pregnancy (category
Route & Dosage
|Complicated Intra-abdominal Infection
Adult: IV 500 mg q8h x 514 d
Complicated UTI, Including Pyelonephritis
Adult: IV 500 mg q8h x 10 d
Clcr ≥30 mL/min but ≤50 mL/min:
250 mg q8h; >10 mL/min but <30 mL/min: 250 mg q12h
PREPARE: Intermittent: Add 10 mL of sterile water for injection or NS to the vial, gently shake to form suspension; yields 50 mg/mL. Preparation of 500 mg dose: Withdraw contents of vial with a 21 gauge needle and add to infusion bag of 100 mL of NS or D5W, gently shake until clear.
Final concentration is 4.5 mg/mL. Preparation of 250 mg dose: Prepare as for the 500 mg dose then remove 55 mL of solution from IV bag and discard. Infuse the remaining solution, which
contains 250 mg (4.5 mg/mL).
ADMINISTER: Intermittent: Infuse over 1530 min.
INCOMPATIBILITIES Solution/additive: Do not combine with any other drug. Y-site: Do not add to Y-site.
Adverse Effects (≥1%)Body as a Whole:
Anaphylaxis, hypersensitivity reactions. CNS: Headache. CV:
Diarrhea, nausea, oral candidiasis. Hematologic:
Elevated hepatic enzymes. Skin:
Doripenem decreases plasma levels of valproic acid. Probenecid
increases doripenem plasma levels.
Minimal protein binding. Metabolism:
In liver (18%) to inactive metabolite. Elimination:
Urine (primarily unchanged). Half-Life:
Assessment & Drug Effects
- Lab tests: Perform C&S tests prior to therapy. Monitor periodically LFTs, Hct & Hgb.
- Determine history of hypersensitivity reactions to other beta-lactams, cephalosporins, penicillins, or other drugs.
- Discontinue drug and immediately report S&S of hypersensitivity (see Appendix F).
- Report S&S of superinfection or pseudomembranous colitis (see Appendix F).
Patient & Family Education
- Learn S&S of hypersensitivity, superinfection, and pseudomembranous colitis; report any of these to physician promptly.